The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats

被引:6
作者
Zarif, A
Eiznhamer, D
Callaghan, C
Doria, MI
Broutman, L
Keshavarzian, A
机构
[1] LOYOLA UNIV,MED CTR,DIV DIGEST DIS & NUTR,SCH MED,DEPT MED,MAYWOOD,IL 60153
[2] LOYOLA UNIV,SCH MED,DEPT PHARMACOL,MAYWOOD,IL 60153
[3] LOYOLA UNIV,SCH MED,DEPT PATHOL,MAYWOOD,IL 60153
[4] ABBOTT LABS,ABBOTT PK,IL 60064
[5] HINES VIRGINIA,MED SERV,HINES,IL
[6] HINES VIRGINIA,RES SERV,HINES,IL
关键词
D O I
10.1007/BF01488200
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Though the mechanism of tissue damage induced by colonic inflammation in ulcerative colitis is unknown, it has been established that the inflammatory mediator and potent neutrophil (PMN) chemotaxin, leukotriene B4(LTB(4)), is present in elevated amounts in the inflamed mucosa. The unique role of 5-lipoxygenase in the production of leukotrienes has made it a target for inhibition. This study used a rat model of acute colonic inflammation induced by a single IP injection of Mitomycin-C to test the efficacy of a specific and potent 5-lipoxygenase inhibitor zileuton in the treatment of colonic inflammation. We hypothesized that after inducing colitis in rats with mitomycin-C, the administration of oral zileuton would inhibit leukotriene production, thus preventing PMN infiltration and subsequent tissue damage. Zileuton decreased colonic tissue damage as measured by Histological score. However, zileuton did not significantly decrease neutrophil infiltration measured by mucosal PMN or myeloperoxidase (MPO) levels. Although zileuton was successful in significantly decreasing the frequency of severe colitis in our model, the fact that the decrease in PMN count and MPO Level was not statistically significant suggests that another mechanism may be involved in its anti-inflammatory effect.
引用
收藏
页码:217 / 227
页数:11
相关论文
共 22 条
[1]  
BELL RL, 1993, ANN NY ACAD SCI, V696, P205
[2]  
COLLAWN C, 1992, AM J GASTROENTEROL, V87, P342
[3]   EICOSANOIDS AND INFLAMMATORY BOWEL-DISEASE - REGULATION AND PROSPECTS FOR THERAPY [J].
FRETLAND, DJ ;
DJURIC, SW ;
GAGINELLA, TS .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1990, 41 (04) :215-233
[4]   THE EFFECT OF METHOTREXATE ON LIPOXYGENASE METABOLISM IN NEUTROPHILS FROM RATS - IN-VITRO AND EX-VIVO STUDIES [J].
HAWKES, JS ;
CLELAND, LG ;
JAMES, MJ .
AGENTS AND ACTIONS, 1993, 40 (3-4) :181-185
[5]   HUMORAL IMMUNE SYSTEM IN INFLAMMATORY BOWEL-DISEASE .2. IMMUNOGLOBULIN LEVELS [J].
HODGSON, HJF ;
JEWELL, DP .
AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1978, 23 (02) :123-128
[6]  
KENNEDY NP, 1987, PHARMACOL THERAPEUT, V1, P263
[7]  
KESHAVARZIAN A, 1992, J LAB CLIN MED, V120, P778
[8]   EXCESSIVE PRODUCTION OF REACTIVE OXYGEN METABOLITES BY INFLAMED COLON - ANALYSIS BY CHEMILUMINESCENCE PROBE [J].
KESHAVARZIAN, A ;
SEDGHI, S ;
KANOFSKY, J ;
LIST, T ;
ROBINSON, C ;
IBRAHIM, C ;
WINSHIP, D .
GASTROENTEROLOGY, 1992, 103 (01) :177-185
[9]   ROLE OF REACTIVE OXYGEN METABOLITES IN EXPERIMENTAL COLITIS [J].
KESHAVARZIAN, A ;
MORGAN, G ;
SEDGHI, S ;
GORDON, JH ;
DORIA, M .
GUT, 1990, 31 (07) :786-790
[10]   RECENT DEVELOPMENTS IN NONSPECIFIC INFLAMMATORY BOWEL-DISEASE .2. [J].
KIRSNER, JB ;
SHORTER, RG .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (14) :837-848